Puma Biotechnology Inc. (NYSE:PBYI)

CAPS Rating: 1 out of 5

Results 1 - 5 of 5

Recs

0
Member Avatar clangmead (24.99) Submitted: 5/15/2015 6:47:18 AM : Outperform Start Price: $170.23 PBYI Score: +11.89

buyout candidate

Recs

1
Member Avatar lookbeforeuleap (93.19) Submitted: 11/15/2014 6:58:54 PM : Outperform Start Price: $28.68 PBYI Score: +527.65

a 10 bagger from 3/13/2013

Recs

0
Member Avatar CramersSkeeDaddy (97.65) Submitted: 7/23/2014 2:04:00 PM : Underperform Start Price: $232.10 PBYI Score: +24.95

up 300% in one day, enough said. Hopefully they do cure/treat all cancer but the short squeeze will likely end soon. No or little revenue, or earnings.

Recs

0
Member Avatar dabhsar (< 20) Submitted: 6/2/2013 8:56:29 AM : Outperform Start Price: $39.55 PBYI Score: +352.70

This small Bio Tech company is onto key medicine break through.

Recs

0
Member Avatar IBDContrarian (22.64) Submitted: 4/6/2013 1:50:39 PM : Underperform Start Price: $30.95 PBYI Score: -479.66

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MEDICAL 1 96 -- A- NO EARN

Results 1 - 5 of 5

Featured Broker Partners


Advertisement